SCHEMBL655368

SCHEMBL655368

CCOC(=O)[C@H](C)Nc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.53
GAA P10253 3/20 0.53
MMP8 P22894 2/20 0.49
PIN1 Q13526 1/20 0.49
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
KMT2A Q03164 1/20 0.47
CA12 O43570 3/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA9 Q16790 3/20 0.47
TSHR P16473 2/20 0.47
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8031605 1.00 ELANE (0.53) ELANEGAAMMP8PIN1MEN1
SCHEMBL6026706 1.00 ELANE (0.53) ELANEGAAMMP8PIN1MEN1
Hydrochloric Acid SCHEMBL1171032 0.98 ELANE (0.52) ELANEGAAMMP8PIN1MEN1
SCHEMBL5954163 0.88 ELANE (0.47) ELANEMMP8CA12CA1CA2
SCHEMBL5954162 0.88 ELANE (0.47) ELANEMMP8CA12CA1CA2
SCHEMBL11675151 0.86 GAA (0.53) ELANEGAAMEN1KMT2AMAPT
Hydrochloric Acid SCHEMBL27296354 0.86 ELANE (0.46) ELANEMMP8PIN1CA12CA1
Hydrochloric Acid SCHEMBL10528752 0.85 GAA (0.51) ELANEGAAMEN1KMT2AMAPT
SCHEMBL27631537 0.84 GAA (0.54) GAAMMP8PIN1MEN1NPC1
SCHEMBL2960871 0.84 CA12 (0.62) GAAMMP8PIN1MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3342599-B1 HEAT-SENSITIVE RECORDING MATERIAL SANKO CO LTD (JP) 2021-06-16 EP disclosed
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses Rigel Pharmceuticals, Inc. (US) 2020-11-10 US disclosed
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2020-07-14 US disclosed
US-10682350-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2020-06-16 US disclosed
US-20200085820-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2020-03-19 US disclosed
US-20190255047-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2019-08-22 US disclosed
US-10369148-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2019-08-06 US disclosed
US-10314840-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2019-06-11 US disclosed
US-10086634-B2 Heat-sensitive recording material SANKO CO., LTD. (JP) 2018-10-02 US disclosed
WO-2000056708-A1 CATALYTIC ASYMMETRIC SYNTHESIS OF CHIRAL AZIRIDINES ARCH DEVELOPMENT CORPORATION (US) 2000-09-28 WO disclosed
EP-0786690-B1 Silver halide light sensitive emulsion layer having enhanced photographic sensitivity EASTMAN KODAK CO (US) 2000-03-22 EP disclosed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 EP disclosed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO disclosed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO disclosed
US-5747235-A SILVER HALIDE ADSORBERS IN EMULSIONS FOR PHOTOGRAPHIC FILMS EASTMAN KODAK COMPANY (US) 1998-05-05 US disclosed
CN-1162761-A Silver halide photographic emulsion layer with enhanced photosensitivity EASTMAN KODAK CO (US) 1997-10-22 CN disclosed
EP-0786690-A2 Silver halide light sensitive emulsion layer having enhanced photographic sensitivity EASTMAN KODAK COMPANY (US) 1997-07-30 EP disclosed
US-4238506-A SECONDARY OR TERTIARY AMIDE-SUBSTITUTED BOEHRINGER MANNHEIM GMBH (DE) 1980-12-09 US disclosed
US-4113871-A HYPOGLYCEMICALLY AND HYPOLIPIDEMICALLY ACTIVE DERIVATIVES OF PHENYL-ALKANE-CARBOXYLIC ACIDS BOEHRINGER MANNHEIM GMBH (DE) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200085820-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885
US-10086634-B2 Heat-sensitive recording material ASIC1, SCN1A, NPR1 ELANE 3647/4885GAA 4231/4885MMP8 3077/4885
US-10682350-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885
US-10314840-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885
US-10369148-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885
US-20190255047-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ELANE 1928/4885GAA 2220/4885MMP8 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.